Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition

On Wednesday, Roche Holdings AG (OTC:RHHBY) released its third-quarter sales report. Sales increased 9% year over year to 15.14 billion Swiss francs (~$17.5 billion).

The company’s pharmaceuticals division reported sales of 11.62 billion Swiss francs.

Roche’s top-performing asset was the multiple sclerosis drug Ocrevus; sales increased 11% to 1.69 billion Swiss francs.

Sales of Vabysmo, an age-related macular degeneration (AMD) treatment, surged 59% year over year to 1.02 billion Swiss francs.

Roche reiterated its business outlook, with the growth of around mid-single digits in group sales and the high-single-digit range for core earnings-per-share.

The European drugmaker axed a mid-stage chronic cough program, RG6341.

Roche also axed a Phase 3 trial for divarasib in the second-line treatment of non-small cell lung cancer ...